Use of substance for detecting exosome ca125 in preparation of product for diagnosing or assisting in diagnosing lung diseases
Through the capture technology of exosome treatment fluid and magnetic bead package, the detection specificity and sensitivity of exosome CA125 in lung diseases are improved, and the problem of insufficient detection rate and sensitivity of markers in the prior art is solved, thus achieving the realization of the problem of insufficient marker detection rate and sensitivity. Efficient diagnosis and severity assessment of interstitial lung disease were performed.
Patent Information
- Application Number
- PCT/CN2024/089354
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-04-23
- Publication Date
- 2024-11-21
AI Technical Summary
The detection rate and sensitivity of existing lung diseases, especially interstitial lung diseases, are not high enough to effectively screen and monitor disease progression. The traditional serum marker CA125 in lung diseases Limited application.
An exosome treatment solution was developed, containing buffer substances, ionic strength maintainers, sealants, surfactants, chelators and sugars, for pretreatment of exosome samples, combined with magnetic bead packs to capture antibodies and luminescence The detection antibody of substance labeling achieves high sensitivity detection of exosome CA125 protein.
It significantly improves the specificity and sensitivity of exosome CA125 in the diagnosis and auxiliary diagnosis of lung disease, has better clinical value and promotion prospects, and can effectively evaluate the severity of lung disease and pulmonary fibrosis.
Smart Images

Figure CN2024089354_21112024_PF_FP_ABST
Abstract
Description
Application of substances for detecting exosomal CA125 in the preparation of products for diagnosing or assisting in the diagnosis of lung diseases
[0001] Related applications
[0002] This application claims priority to Chinese patent application No. 2023105475792 filed on May 15, 2023, the contents of which are incorporated herein by reference in their entirety for all purposes. Technical Field
[0003] The present invention belongs to the field of biological detection technology, and specifically relates to the use of a substance for detecting exosomal CA125 in the preparation of products for diagnosing or assisting in the diagnosis of lung diseases. Background Art
[0004] Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by progressive dyspnea and dry cough. Lesions occur in the lung parenchyma, accompanied by extensive inflammation and diffuse fibrosis. Pulmonary fibrosis, a common manifestation of ILD, is characterized by alveolar epithelial cell damage, diffuse localized alveolitis, pathological interstitial proliferation of fibroblasts, and deposition of extracellular matrix (ECM) in the interstitial and alveolar regions, leading to irreversible lung structural remodeling and functional loss, impaired gas exchange, and even respiratory failure. Early diagnosis of ILD and pulmonary fibrosis can guide medication and improve prognosis. Common diagnostic methods include pulmonary function tests, chest HRCT, and invasive bronchoalveolar lavage fluid analysis and lung biopsy. Therefore, serological tests for early screening and progression monitoring of ILD have become a promising research direction in recent years.
[0005] Currently, serum markers used clinically to aid in the diagnosis of ILD include sialolyzed carbohydrate antigen (KL-6), but its detection rate and sensitivity are insufficient, hindering widespread use. The carbohydrate antigen CA125 is currently the most widely used serum tumor marker. It is primarily expressed in the mesothelium, Müllerian epithelium, and coelomic epithelial tissues derived from Müllerian ducts. Tissue lesions or abnormal proliferation in these tissues can lead to a significant increase in CA125 levels. Multiple studies have confirmed that the positivity rate of CA125 in the serum of lung cancer patients can reach 60% to 70%. Furthermore, studies have demonstrated a significant correlation between serum CA125 and ILD, and that it can differentiate idiopathic pulmonary fibrosis (IPF) from other ILDs.
[0006] Exosomes are extracellular vesicles with diameters ranging from 30 to 150 nm, with an average diameter of 100 nm. They are formed by invagination of the cytoplasmic membrane and fusion with other intracellular vesicles and organelles. Exosomes carry a rich supply of proteins, nucleic acids, lipids, and metabolites, which can mediate cell-to-cell communication by regulating downstream signaling pathways in recipient cells.
[0007] Exosomes play a crucial role in the development and progression of diseases, offering unique advantages and potential value in disease diagnosis and treatment. Proteins contained in exosomes have also been extensively studied as potential biomarkers. CA125, a glycoprotein expressed by the MUC16 gene and present on the cell membrane, has recently been shown to be present in ovarian cancer exosomes at higher levels than free CA125 in the blood. However, the diagnostic application of exosome-derived CA125 in lung disease has not yet been reported.
[0008] Summary of the Invention
[0009] The first aspect of the present invention aims to provide an exosome processing solution.
[0010] The second aspect of the present invention aims to provide an application of the exosome processing solution of the first aspect of the present invention.
[0011] The third aspect of the present invention aims to provide a reagent.
[0012] The fourth aspect of the present invention aims to provide a kit.
[0013] The fifth aspect of the present invention aims to provide a detection system.
[0014] The sixth aspect of the present invention aims to provide a method for detecting the presence or content of exosome proteins.
[0015] The seventh aspect of the present invention aims to provide a method for detecting exosomal CA125 and its use in preparing products.
[0016] In order to achieve the above object, the technical solution adopted by the present invention is:
[0017] In a first aspect, the present invention provides an exosome processing solution comprising the following components: a buffer substance, an ionic strength maintaining agent, a blocking agent, a surfactant, a chelating agent, and a carbohydrate.
[0018] Preferably, the content of the buffer substance in the exosome processing solution is 2-4% by weight; further 2.2-3.8% by weight.
[0019] Preferably, the buffer substance comprises at least one of borax salt, tris (hydroxymethyl)aminomethane (Tris), phosphate buffer salt, acetate buffer salt, and citrate buffer salt; and further comprises tris (hydroxymethyl)aminomethane (Tris) and phosphate buffer salt.
[0020] Preferably, the content of tris (hydroxymethyl)aminomethane (Tris) in the exosome processing solution is 0.9-2.1% by weight; further 1-2% by weight.
[0021] Preferably, the content of the phosphate buffer in the exosome processing solution is 1.1-1.9% by weight; further 1.2-1.8% by weight.
[0022] Preferably, the phosphate buffer salt is at least one of sodium phosphate, potassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate and sodium dihydrogen phosphate; further a mixture of disodium hydrogen phosphate and sodium dihydrogen phosphate.
[0023] Preferably, the weight ratio of disodium hydrogen phosphate to sodium dihydrogen phosphate is 1:(0.7-1.1); further 1:(0.8-1).
[0024] Preferably, the disodium hydrogen phosphate is disodium hydrogen phosphate dodecahydrate.
[0025] Preferably, the sodium dihydrogen phosphate is sodium dihydrogen phosphate dihydrate.
[0026] Preferably, the ionic strength maintaining agent comprises a chloride salt; further comprises at least one of potassium chloride, sodium chloride, calcium chloride and magnesium chloride; further comprises sodium chloride.
[0027] Preferably, the content of the ionic strength maintaining agent in the exosome processing solution is 0.6-1.2% by weight; further 0.8-1% by weight.
[0028] Preferably, the blocking agent comprises at least one of bovine serum albumin (BSA), casein, and collagen peptide.
[0029] Preferably, the blocking agent comprises at least one of casein and collagen peptide and BSA.
[0030] Preferably, the blocking agent comprises BSA.
[0031] Preferably, the content of the blocking agent in the exosome processing solution is 0.8-2.2% by weight; further 1-2% by weight.
[0032] Preferably, the surfactant comprises at least one of anionic surfactants, cationic surfactants, zwitterionic surfactants, and nonionic surfactants; further comprises a nonionic surfactant, for example: a nonionic surfactant containing a polyoxyethylene alcohol structure (for example, alcohol ethoxylates, polyoxyethylene-polyoxyalkylene block copolymers), polyoxyethylene sorbitan fatty acid esters (for example, TWEEN (registered trademark) series (for example, Tween-20, Tween-40, Tween-80)), polyoxyethylene octylphenyl ether (for example, TRITON (registered trademark) series (for example, Triton X-100, Triton X-114, Triton X-305, Triton X-405, Triton X-705)), ND-glucose-N-methylalkaneamide (for example, MEGA series (for example, MEGA 8, MEGA 10); further comprises Tween-20.
[0033] Preferably, the content of the surfactant in the exosome processing liquid is 0.05-0.6% by weight; further 0.1-0.5% by weight.
[0034] Preferably, the chelating agent comprises at least one of ethylenediaminetetraacetic acid and a water-soluble salt of ethylenediaminetetraacetic acid; further comprises a water-soluble salt of ethylenediaminetetraacetic acid; and further comprises disodium ethylenediaminetetraacetic acid.
[0035] Preferably, the content of the chelating agent in the exosome processing solution is 0.03-0.25% by weight; further 0.05-0.2% by weight.
[0036] Preferably, the sugar comprises at least one of sucrose and trehalose; and further comprises trehalose.
[0037] Preferably, the content of the sugar in the exosome processing solution is 0.8-2.2% by weight; further 1-2% by weight.
[0038] Preferably, the exosome processing solution further comprises a preservative.
[0039] Preferably, the preservative comprises at least one of sodium azide, Proclin 300, 5-bromo-5-nitro-1,3-dioxane (BND), and Proclin 900; and further comprises sodium azide or Proclin 300.
[0040] Preferably, the content of the preservative in the exosome processing liquid is 0.08-0.22% by weight; further 0.1-0.2% by weight.
[0041] Preferably, the exosome processing liquid further comprises water, and the amount of water used is the balance.
[0042] Preferably, the pH of the exosome treatment solution is 6-8; further 7-8; further 7.5.
[0043] Preferably, the exosomes are derived from: whole blood, serum, plasma, bronchoalveolar lavage fluid, urine or one or more combinations thereof.
[0044] The second aspect of the present invention provides the use of the exosome processing solution of the first aspect of the present invention in at least one of a1) to a6);
[0045] a1) Detecting the presence of exosomal substances;
[0046] a2) Detecting the content of exosome substances;
[0047] a3) preparing products for diagnosing or assisting in the diagnosis of diseases, wherein the diseases are diagnosed or assist in the diagnosis based on the presence or absence or content of exosome substances;
[0048] a4) preparing a product for assessing the severity of a disease, wherein the severity of the disease is assessed by the content of exosome substances;
[0049] a5) preparing a product for detecting the presence or absence of exosome substances;
[0050] a6) preparing a product for detecting the content of exosome substances;
[0051] The substance comprises at least one of nucleic acid and protein.
[0052] Preferably, the nucleic acid comprises at least one of DNA and RNA.
[0053] Preferably, the substance comprises protein.
[0054] Preferably, the product comprises at least one of a reagent, a kit, and a detection system.
[0055] Preferably, the applications described in a1) and a2) are for non-diagnostic purposes.
[0056] Preferably, the exosomes are derived from: whole blood, serum, plasma, bronchoalveolar lavage fluid, urine or one or more combinations thereof.
[0057] The third aspect of the present invention provides a reagent comprising the exosome processing solution of the first aspect of the present invention.
[0058] Preferably, the reagent is used for at least one of b1) to b4):
[0059] b1) Detecting the presence or absence of exosomal substances;
[0060] b2) detecting the content of exosome substances;
[0061] b3) diagnosing or assisting in the diagnosis of a disease, wherein the disease is diagnosed or assists in the diagnosis based on the presence or absence or content of exosome substances;
[0062] b4) evaluating the severity of the disease, wherein the severity of the disease is evaluated by the content of exosome substances.
[0063] The substance comprises at least one of nucleic acid and protein.
[0064] Preferably, the nucleic acid comprises at least one of DNA and RNA.
[0065] Preferably, the substance comprises protein.
[0066] Preferably, the exosomes are derived from: whole blood, serum, plasma, bronchoalveolar lavage fluid, urine or one or more combinations thereof.
[0067] Preferably, the reagent is used for pre-treating exosomes and then used for at least one of b1) to b4).
[0068] A fourth aspect of the present invention provides a kit comprising at least one of c1) to c2):
[0069] c1) the exosome processing solution according to the first aspect of the present invention;
[0070] c2) The reagent according to the third aspect of the present invention.
[0071] Preferably, the kit is used for at least one of b1) to b4) of the third aspect of the present invention.
[0072] Preferably, a kit comprises at least one of c1) to c2), magnetic beads coated with capture antibodies, and detection antibodies labeled with luminescent substances:
[0073] c1) the exosome processing solution according to the first aspect of the present invention;
[0074] c2) the reagent according to the third aspect of the present invention;
[0075] The kit is used for at least one of d1) to d4):
[0076] d1) Detecting the presence of exosomal proteins;
[0077] d2) Detecting the content of exosomal proteins;
[0078] d3) diagnosing or assisting in the diagnosis of a disease, wherein the disease is diagnosed or assists in the diagnosis based on the presence or content of exosome proteins;
[0079] d4) evaluating the severity of the disease, wherein the severity of the disease is evaluated by the content of exosomal proteins;
[0080] The capture antibody and / or the detection antibody specifically binds to the protein.
[0081] Preferably, the capture antibody and the detection antibody are directed against different antigenic epitopes of the protein, respectively.
[0082] Preferably, the luminescent substance comprises at least one of acridinium ester, horseradish peroxidase, and alkaline phosphatase; and further comprises acridinium ester.
[0083] Preferably, the kit further comprises at least one of a luminescent substrate and a protein calibrator; further comprises a luminescent substrate and a protein calibrator.
[0084] Preferably, the luminescent substrate comprises at least one of APS-5 or AMPPD buffer (with supporting alkaline phosphatase), acridinium ester pre-excitation solution and excitation solution (with supporting acridinium ester), luminol or isoluminol buffer (with supporting horseradish peroxidase).
[0085] Preferably, the protein is CA125, and the kit is used for at least one of e1) to e5):
[0086] e1) Detection of the presence of exosomal CA125;
[0087] e2) Detection of exosomal CA125 content;
[0088] e3) Diagnosis or auxiliary diagnosis of lung diseases;
[0089] e4) Assess the severity of lung disease;
[0090] e5) Diagnosis or auxiliary diagnosis of pulmonary fibrosis.
[0091] Preferably, the lung disease comprises pneumonia or interstitial lung disease.
[0092] Preferably, the exosomes are derived from: whole blood, serum, plasma, bronchoalveolar lavage fluid, urine or one or more combinations thereof.
[0093] A fifth aspect of the present invention provides a detection system comprising at least one of f1) to f3) and a chemiluminescence analyzer;
[0094] f1) the exosome processing solution according to the first aspect of the present invention;
[0095] f2) the reagent according to the third aspect of the present invention;
[0096] f3) The kit according to the fourth aspect of the present invention.
[0097] Preferably, the detection system is used for at least one of b1) to b4) in the third aspect of the present invention, or at least one of d1) to d4) in the fourth aspect of the present invention.
[0098] A sixth aspect of the present invention provides a method for detecting the presence or content of exosome proteins, comprising the step of pre-treating the exosomes using the exosome processing solution of the first aspect of the present invention.
[0099] Preferably, the step of pre-treating the exosomes using the exosome treatment solution of the first aspect of the present invention is as follows: mixing the exosome treatment solution with the exosomes and reacting them.
[0100] Preferably, the volume ratio of the exosome treatment solution to the exosomes is 1:(2-30), for example, it can be 1:2, 1:5, 1:9, 1:10, 1:12, 1:15, 1:18, 1:20, 1:22, 1:25, 1:28 or 1:30, etc.
[0101] Preferably, the reaction time is 5 to 120 min; further 5 to 10 min, for example, 5 min, 6 min, 7 min, 8 min, 9 min or 10 min.
[0102] Preferably, the reaction temperature is 25-42°C; further 35-40°C, for example, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, etc.
[0103] Preferably, the exosomes are derived from: whole blood, serum, plasma, bronchoalveolar lavage fluid, urine or one or more combinations thereof.
[0104] Preferably, the exosome preparation method is any one of a fully automatic exosome extraction instrument or a manual extraction method (such as centrifugation, kit method, ultrafiltration method, magnetic bead immunoassay, polyethylene glycol precipitation method).
[0105] Preferably, the method further comprises the following steps:
[0106] (1) mixing the pretreated exosomes with magnetic beads coated with capture antibodies, reacting to obtain magnetic beads-exosome complexes coated with capture antibodies;
[0107] (2) mixing the capture antibody-coated magnetic bead-exosome complex with the luminescent-labeled detection antibody, and reacting them to obtain the capture antibody-coated magnetic bead-exosome-luminescent-labeled detection antibody complex;
[0108] (3) The magnetic beads coated with the capture antibody-exosome-luminescent detection antibody complex is mixed with the luminescent substrate, reacted, and the luminescence intensity is detected to obtain the protein content in the exosome sample.
[0109] Preferably, the reaction time in steps (1) and (2) is 5 to 120 min; further 5 to 10 min, for example, 5 min, 6 min, 7 min, 8 min, 9 min or 10 min.
[0110] Preferably, the reaction temperature in steps (1) and (2) is 25-42°C; further 35-40°C, for example, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, etc.
[0111] Preferably, the method for obtaining the protein content in the exosome sample in step (3) is: using a protein calibrator to construct a standard curve by a standard curve method, and then calculating the protein content in the exosome sample based on the detected luminescence intensity.
[0112] Preferably, the magnetic beads coated with capture antibodies, the detection antibodies labeled with luminescent substances, and the luminescent substrate are the magnetic beads coated with capture antibodies, the detection antibodies labeled with luminescent substances, and the luminescent substrate in the fourth aspect of the present invention.
[0113] Preferably, the method for preparing the magnetic beads coated with the capture antibody is a common method in the art, specifically as follows: the activated magnetic beads are mixed with the capture antibody, incubated, and blocked to obtain.
[0114] Preferably, the mass ratio of the activated magnetic beads to the capture antibody is 100:(1-10); further 100:(1-4); further 100:(2-3).
[0115] Preferably, the preparation method of the activated magnetic beads is: mixing magnetic beads, EDC and NHS, and reacting to obtain.
[0116] Preferably, the mass ratio of the magnetic beads, EDC and NHS is (0.03-0.07): (0.06-0.14):1.
[0117] Preferably, the magnetic beads are a magnetic bead activation buffer containing magnetic beads.
[0118] Preferably, the reaction is carried out at room temperature for 15 to 120 minutes.
[0119] Preferably, the incubation time is 1 to 4 hours.
[0120] Preferably, the specific method of blocking is: mixing the mixture of the activated magnetic beads and the capture antibody after incubation with a blocking agent.
[0121] Preferably, the amount of the mixture of the activated magnetic beads and the capture antibody after incubation and the blocking agent is 1:(2-10) by mass ratio; further 1:(2-5) by mass ratio.
[0122] Preferably, after the blocking step, the method further comprises the following steps: removing the supernatant by magnetic separation, and then diluting with a diluent.
[0123] Preferably, the diluent is composed of the following components by weight percentage: Tris 0.05-0.1%, NaCl 0.9-3.0%, BSA 1-3%, Tween-20 0.1-0.5%, sodium azide 0.1-0.2%, and water as the balance, with a pH of 7.5.
[0124] Preferably, the preparation method of the luminescent substance-labeled detection antibody is a common method in the art, specifically as follows: mixing the luminescent substance with the detection antibody, incubating, and quenching to obtain.
[0125] Preferably, the incubation time is 30 to 120 minutes.
[0126] Preferably, the specific method of quenching is: mixing the mixed solution of the incubated luminescent substance and the detection antibody with a quencher and reacting them.
[0127] Preferably, the reaction time is 30 to 120 minutes.
[0128] Preferably, after the quenching, the following steps are further included: purification and dilution with a diluent.
[0129] Preferably, the purification method comprises dialysis or desalting column treatment.
[0130] Preferably, the diluent is composed of the following components by weight percentage: MES 0.05-0.1%, NaCl 0.9-3.0%, BSA 1-3%, Tween-20 0.1-0.5%, sodium azide 0.1-0.2%, and water as the balance, with a pH of 6.5.
[0131] Preferably, the method is a non-disease diagnostic method.
[0132] A seventh aspect of the present invention provides use of a substance for detecting exosomal CA125 in preparing a product;
[0133] The product is used for at least one of g1) to g3):
[0134] g1) Diagnosis or auxiliary diagnosis of lung diseases;
[0135] g2) Assess the severity of lung disease;
[0136] g3) Diagnosis or auxiliary diagnosis of pulmonary fibrosis.
[0137] Preferably, the lung disease comprises pneumonia or interstitial lung disease.
[0138] Preferably, the substance for detecting CA125 includes a substance for detecting CA125 at the gene level and / or protein level; and further includes a substance for detecting CA125 at the protein level.
[0139] Preferably, the product is a reagent, a kit, a detection chip or a detection system.
[0140] Preferably, the product comprises the exosome processing solution according to the first aspect of the present invention.
[0141] The beneficial effects of the present invention are:
[0142] The present invention provides an exosome processing liquid. Using the exosome processing liquid provided by the present invention to pretreat the exosome sample to be tested can reduce the impact of components in the eluate on the detection of exosome proteins, effectively shorten the detection time, achieve stable detection of exosome proteins, and facilitate the realization of fully automated detection of exosome proteins.
[0143] The present invention discloses for the first time the use of exosomal CA125 as a marker for the diagnosis, auxiliary diagnosis, severity assessment and / or diagnosis of lung diseases and pulmonary fibrosis. Compared with the traditional marker - serum CA125, this method has better diagnostic effect: higher specificity and sensitivity, and has important clinical value and promotion prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0144] FIG1 is a graph showing the results of detecting the CA125 protein content on exosomes using the detection methods provided in Comparative Example 1, Comparative Example 2, and Example 5 in Effect Example 2.
[0145] FIG2 is a ROC curve diagram of serum CA125 and exosome CA125 for diagnosing interstitial lung disease in Example 3.
[0146] Figure 3 is a graph showing the results of detecting the CA125 protein content on exosomes in healthy people, ILD-positive and marketed serum KL-6 detection reagent-negative samples, and ILD-positive and marketed serum KL-6 detection reagent-positive samples in Example 4 using the detection method provided in Example 5. DETAILED DESCRIPTION
[0147] The present invention is further described in detail below through specific examples.
[0148] It should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0149] The experimental methods in the following examples, where specific conditions are not specified, were generally performed under conventional conditions or the conditions recommended by the manufacturers. The materials and reagents used in these examples were commercially available unless otherwise specified.
[0150] The abbreviations and key terms in this embodiment are defined as follows:
[0151] Tris: tris(hydroxymethyl)aminomethane;
[0152] BSA: bovine serum albumin;
[0153] Tween-20: Tween 20;
[0154] EDTA-2Na: disodium ethylenediaminetetraacetate;
[0155] MES: morpholineethanesulfonic acid;
[0156] EDC: 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride;
[0157] NHS: N-hydroxysuccinimide;
[0158] BND: 5-bromo-5-nitro-1,3-dioxane.
[0159] Example 1: An exosome processing solution
[0160] An exosome processing solution is composed of the following components, by weight percentage: 1% Tris, 0.6% disodium hydrogen phosphate dodecahydrate, 0.6% sodium dihydrogen phosphate dihydrate, 0.8% NaCl, 1% BSA, 0.1% Tween-20, 0.05% EDTA-2Na, 1% trehalose, 0.1% sodium azide, and the balance water; pH 7.5.
[0161] Example 2: An exosome processing solution
[0162] An exosome processing solution is composed of the following components, by weight percentage: Tris 2%, disodium hydrogen phosphate dodecahydrate 1%, sodium dihydrogen phosphate dihydrate 0.8%, NaCl 1%, BSA 2%, Tween-20 0.5%, EDTA-2Na 0.2%, trehalose 2%, sodium azide 0.2%, and water as the balance; pH 7.5.
[0163] Example 3: An exosome processing solution
[0164] An exosome processing solution is composed of the following components, by weight percentage: 1.5% Tris, 0.8% disodium hydrogen phosphate dodecahydrate, 0.7% sodium dihydrogen phosphate dihydrate, 0.9% NaCl, 1.5% BSA, 0.3% Tween-20, 0.1% EDTA-2Na, 1.5% trehalose, 0.15% sodium azide, and the balance water; pH 7.5.
[0165] Example 4: An exosome processing solution
[0166] An exosome processing solution consists of the following components, by weight percentage: 1% Tris, 0.6% disodium hydrogen phosphate dodecahydrate, 0.6% sodium dihydrogen phosphate dihydrate, 0.8% NaCl, 1% BSA, 0.1% Tween-20, 0.05% EDTA-2Na, 1% trehalose, 0.1% proclin 300, and the balance water; pH 7.5.
[0167] Example 5 A method for detecting CA125 protein on exosomes
[0168] A method for detecting CA125 protein on exosomes comprises the following steps:
[0169] (1) Preparation of magnetic bead coatings
[0170] 1) Magnetic Bead Activation: To 1 mL of magnetic bead activation buffer (containing 1% MES in water), add 10 mg of magnetic beads, EDC solution (final concentration 0.5 mg / mL) and NHS solution (final concentration 1 mg / mL), and react at room temperature for 30 min to activate the magnetic beads. Then, remove the supernatant by magnetic separation.
[0171] 2) Antibody Coupling: 10 mg of magnetic beads were resuspended in 1 mL of magnetic bead coupling buffer (containing an aqueous solution of 1% MES by mass), 300 μg of CA125 capture antibody (Beijing Kaijing, Catalog No.: BXA003) was added, and the mixture was incubated at room temperature for 2 h to obtain a magnetic bead-antibody conjugate solution.
[0172] 3) Blocking: Add 100 μL of blocking agent (1% bovine serum albumin aqueous solution) to the magnetic bead-antibody conjugate solution and incubate at room temperature for 2 h.
[0173] 4) Washing: After removing the supernatant by magnetic separation, add 1 mL of magnetic bead washing solution (PBS buffer containing 0.1% proclin 300 by mass concentration) for washing. Repeat the washing step twice and then remove the supernatant by magnetic separation to obtain magnetic beads coated with CA125 capture antibody (CA125 magnetic bead coating).
[0174] 5) Preparation of Magnetic Bead Coating Working Solution: CA125 magnetic beads were diluted with Magnetic Bead Coating Diluent to obtain a 0.5 mg / mL magnetic bead coating working solution. The magnetic bead coating diluent consisted of the following components by weight: Tris 0.1%, NaCl 2%, BSA 3%, Tween-20 0.5%, sodium azide 0.1%, and the balance water, with a pH of 7.5.
[0175] (2) Preparation of acridinium ester markers
[0176] 1) Preparation of acridinium ester stock solution: Dissolve acridinium ester in anhydrous DMSO to a final concentration of 5 mg / mL.
[0177] 2) Labeling Reaction: Dilute 300 μg of CA125 detection antibody (Beijing Kaijing, Catalog No.: BXA004) with 0.2 M NaHCO3 (pH = 9.0) solution, add 15 μL of acridinium ester stock solution, and adjust the volume to 300 μL. At this time, the acridinium ester concentration is 0.25 mg / mL; wrap the mixture in tin foil, place it on a thermomixer, and label at room temperature for 30 minutes.
[0178] 3) Quenching the reaction: add 100 μL of labeling termination buffer (0.2 M NaHCO 3 solution containing 10% lysine, pH 9.0) and mix at room temperature for 30 minutes.
[0179] 4) Purification: Purify the labeled antibody using a desalting column, collect the acridinium ester labeled protein fraction and detect its concentration to obtain the acridinium ester labeled CA125 detection antibody.
[0180] 5) Preparation of Luminescent-Labeled Antibody Working Solution (Acridinium Ester Labeling Working Solution): Dilute the CA125 detection antibody acridinium ester label with acridinium ester labeling diluent to obtain an acridinium ester labeling working solution with a concentration of 0.4 μg / mL. The acridinium ester labeling diluent is composed of the following components by weight: 0.1% MES, 2% NaCl, 3% BSA, 0.1% Tween-20, 0.1% sodium azide, and the balance water, with a pH of 6.5.
[0181] (3) Exosome sample pretreatment
[0182] 1) Sample pretreatment: Serum or plasma was diluted half with PBS and filtered through a 0.22 μm filter to remove cell debris and other impurities.
[0183] 2) Exosome extraction: Exosomes were extracted using an automatic exosome extractor.
[0184] 10 μL of the exosome sample was mixed with 90 μL of the exosome treatment solution of Example 1 and reacted at 37° C. for 5 min.
[0185] (4) Detection and calculation of CA125 content in exosome samples
[0186] 1) Take 20 μL of the pretreated sample obtained in step (3), add 50 μL of the magnetic bead coating working solution, mix well and incubate at 37°C for 5 minutes; then perform magnetic separation, wash to remove unbound substances, and discard the supernatant to obtain the magnetic bead coating-exosome complex.
[0187] 2) Add 50 μL of luminescent-labeled antibody working solution (acridinium ester labeling working solution) to the magnetic bead-exosome complex, mix well, and incubate at 37°C for 5 min. Then, perform magnetic separation and wash to remove unbound substances to obtain a magnetic bead-exosome-marker complex.
[0188] 3) Add 100 μL of acridinium ester pre-stimulation solution (containing 0.1 wt% of a 30 wt% hydrogen peroxide and 0.2 mol / L nitric acid solution in water) and 100 μL of stimulation solution (containing 0.1 wt% hexadecyltrimethylammonium chloride and 0.2 mol / L sodium hydroxide solution in water) to the obtained magnetic bead-exosome-marker complex. After thorough mixing, measure the maximum luminescence intensity; fit a standard curve based on the luminescence intensity detected by the standard, and calculate the CA125 content in the exosome sample to be tested using the standard curve.
[0189] Example 6 A method for detecting CA125 protein on exosomes
[0190] The detection method of this embodiment is the same as that of Example 5, with the only difference being that step (3) uses the exosome processing solution of Example 2.
[0191] Example 7 A method for detecting CA125 protein on exosomes
[0192] The detection method of this embodiment is the same as that of Example 5, with the only difference being that step (3) uses the exosome processing solution of Example 3.
[0193] Example 8 A method for detecting CA125 protein on exosomes
[0194] The detection method of this embodiment is the same as that of Example 5, with the only difference being that step (3) uses the exosome processing solution of Example 4.
[0195] Example 9 A method for detecting CA125 protein on exosomes
[0196] The detection method of this embodiment is the same as that of Example 5, with the only difference being that the amount of CA125 capture antibody used in step (1) 2) is 200 μg.
[0197] Example 10 A method for detecting CA125 protein on exosomes
[0198] The detection method of this embodiment is the same as that of Example 5, with the only difference being that the amount of CA125 detection antibody used in step (2) 2) is 200 μg.
[0199] Comparative Example 1: A method for detecting CA125 protein on exosomes
[0200] The detection method of this embodiment is the same as that of embodiment 5, except that the exosome sample is not pretreated, that is, step (3) is not included.
[0201] Comparative Example 2: A method for detecting CA125 protein on exosomes
[0202] The detection method of this example is the same as that of Example 5, except that the exosome processing solution of Example 1 is replaced with a commercially available PBS buffer solution (Shanghai Biyuntian Biotechnology Co., Ltd., catalog number: ST447).
[0203] Effect Example 1
[0204] Effect of exosome pretreatment solution on dilution and recovery of exosome CA125 protein detection results
[0205] For serum CA125-positive samples, exosomes were extracted using a kit to obtain a stock solution. The solution was diluted 2-fold and 4-fold using PBS buffer. The CA125 protein content in the exosomes was then assayed using the detection methods described in Examples 5-10 and Comparative Examples 1-2, respectively, on a fully automatic chemiluminescence immunoassay (model: Shine i2910). The dilution recovery was calculated based on the luminescence values of the stock solution, the 2-fold dilution, and the 4-fold dilution. After dilution, the sample was allowed to stand at room temperature for over 1 hour before being assayed simultaneously with the stock solution.
[0206] The results are shown in Table 1: After pretreatment with the exosome treatment solution provided by the present invention (Examples 5-10), the dilution recovery rate of exosome protein detection was 92-112%, which was significantly better than no pretreatment or pretreatment with PBS buffer (Comparative Examples 1-2). It can be seen that the use of the exosome treatment solution provided by the present invention to pretreat the exosome sample to be tested reduces the interference of high salt and surfactant components in the eluate on exosome protein detection by diluting the exosome sample, which is conducive to the realization of fully automated detection of exosome protein.
[0207] Table 1 Effects of exosome treatment solution on exosome CA125 protein detection results
[0208] Effect Example 2
[0209] Effect of exosome pretreatment solution on the significance of differences in exosome CA125 protein detection results
[0210] Eight healthy human serum (CN) samples and eight ILD-positive (ILD) samples were collected and the CA125 protein content on exosomes was detected using the detection methods provided in Comparative Example 1, Comparative Example 2, and Example 5. The significance of the differences among the three methods was evaluated. The results are shown in Figure 1: there was no significant difference in the results using the detection method of Comparative Example 1, the results using the detection method of Comparative Example 2 were significantly different (p < 0.05), and the results using the detection method of Example 5 were extremely significantly different (p < 0.001).
[0211] Effect Example 3
[0212] Comparison of serum CA125 and exosome CA125 detection results between healthy subjects and ILD patients
[0213] 20 serum samples from healthy people, 20 samples that were ILD-positive and had negative results using the marketed serum KL-6 detection reagent, and 20 samples that were ILD-positive and had positive results using the marketed serum KL-6 detection reagent; CA125 in 60 sera was detected using a commercially available serum CA125 kit; the detection method provided in Example 5 was used to detect the CA125 protein content on exosomes; ROC analysis was performed on the two parts of the results, and the results are shown in Figure 2: The samples were defined as positive or negative based on the clinical diagnosis of interstitial lung disease, and ROC curves were prepared for each. The AUC of the ROC curve for CA125 on exosomes (serum-exo) was 0.88, and the AUC of the ROC curve for serum CA125 (serum) was 0.83. It can be seen that the diagnostic effect of CA125 on exosomes (serum-exo) is better than that of serum CA125 (serum). Based on the AUC, the cutoff value for exosomal CA125 is 11,000, with a sensitivity of 90%. The cutoff value for serum CA125 is 115,000, with a sensitivity of 70%. The sensitivity of exosomal CA125 is higher than that of serum CA125, indicating that exosomal CA125 has a higher sensitivity as a marker for lung diseases such as ILD.
[0214] Effect Example 4
[0215] Comparison of CA125 detection results on exosomes between healthy subjects and ILD patients
[0216] 20 serum samples from healthy people, 20 samples with negative results of ILD-positive and marketed serum KL-6 detection reagent, and 20 samples with positive results of ILD-positive and marketed serum KL-6 detection reagent were taken; the detection method provided in Example 5 was used to detect the content of CA125 protein on exosomes; the results are shown in Table 2 and Figure 3: In patients with ILD who were serum KL-6 positive, the luminescence values of CA125 protein detection on their exosomes were significantly higher than those of CA125 protein detection on exosomes of healthy people samples (P<0.0001), and the luminescence values of CA125 protein detection on their serum were significantly higher than those of CA125 protein detection on exosomes of healthy people samples (P<0.01), but the significance was less than that of CA125 on exosomes; in patients with ILD who were serum KL-6 negative, There was no statistical difference in the luminescence value of serum CA125 protein detection between the patients and the healthy group (P=0.942), while the luminescence value of exosome CA125 protein detection tended to be higher than that of exosome CA125 protein detection in healthy group samples (P=0.061). It can be seen that exosome CA125 detection can, to a certain extent, distinguish some ILD-positive patient samples with serum KL-6-negative from healthy group samples (the effect is better than serum CA125), and has a better diagnostic effect.
[0217] Table 2 Comparison of CA125 detection results on exosomes between healthy subjects and ILD patients
[0218] Effect Example 5
[0219] Exosomal CA125 for the diagnosis of interstitial lung disease
[0220] According to the luminescence value of CA125 on the exosomes of healthy people and ILD patient samples in Example 3, the cutoff value in the exosome CA125 detection method can be preliminarily determined to be 11000. According to the cutoff, the positive and negative test results of the exosome CA125 test results of the ILD patient samples are determined, and then the correlation between the positive and negative test results and the clinical symptoms of the ILD patients is evaluated. The results are shown in Table 3: Combining the test results of Table 2 and Table 3, the exosome CA125 cutoff value is preliminarily determined to be 11000. For ILD patients whose test results of the serum KL-6 detection kit on the market are negative (<500U / mL), the exosome CA125 detection rate is 35% (7 / 20); This shows that exosome CA125 has a higher detection rate of interstitial pneumonia in serum KL-6 negative samples than the serum KL-6 detection kit. In addition, by comparing the correlation between exosome CA125 and serum KL-6 values and the clinical manifestations of ILD positive patients, in 7 cases of serum KL-6 negative and CA125 positive Among the patients, 1 developed respiratory failure and 1 developed idiopathic interstitial pneumonia; among the 11 patients with positive exosomal CA125 and serum KL-6, 8 were clinically diagnosed with pulmonary fibrosis and 3 developed severe pneumonia / respiratory failure. This shows that exosomal CA125 can be used as a marker to screen out patients with interstitial pneumonia who have developed pulmonary fibrosis or progressed to severe pneumonia, indicating that exosomal CA125 has important potential clinical value in diagnosing interstitial lung disease and assessing the severity of interstitial lung disease.
[0221] Table 3 Results of exosomal CA125 in the diagnosis of interstitial lung disease
[0222] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be considered as equivalent replacement methods and are included in the scope of protection of the present invention.
Claims
1. An exosome processing solution comprising the following components: a buffer substance, an ionic strength maintaining agent, a blocking agent, a surfactant, a chelating agent and a sugar.
2. The exosome processing liquid according to claim 1, characterized in that: The buffer substance comprises at least one of borax salt, tris(hydroxymethylaminomethane), phosphate buffer, acetate buffer, and citrate buffer; Preferably, the ionic strength maintaining agent comprises a chloride salt; Preferably, the blocking agent comprises at least one of bovine serum albumin, casein, and collagen peptide; Preferably, the surfactant comprises at least one of anionic surfactant, cationic surfactant, zwitterionic surfactant and nonionic surfactant; Preferably, the chelating agent comprises at least one of ethylenediaminetetraacetic acid and a water-soluble salt of ethylenediaminetetraacetic acid; Preferably, the sugar comprises at least one of sucrose and trehalose; Preferably, the exosome processing solution further comprises a preservative.
3. The exosome processing liquid according to claim 1 or 2, characterized in that: The preservative comprises at least one of sodium azide, Proclin 300, 5-bromo-5-nitro-1,3-dioxane, and Proclin 900; Preferably, the content of the buffer substance in the exosome processing solution is 2-4% by weight; Preferably, the buffer substance comprises tris(hydroxymethylaminomethane) and phosphate buffer; Preferably, the content of tris(hydroxymethyl)aminomethane in the exosome processing solution is 0.9 to 2.1% by weight; Preferably, the content of the phosphate buffer in the exosome processing solution is 1.1 to 1.9% by weight; Preferably, the phosphate buffer is at least one of sodium phosphate, potassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate and sodium dihydrogen phosphate; further a mixture of disodium hydrogen phosphate and sodium dihydrogen phosphate; Preferably, the weight ratio of disodium hydrogen phosphate to sodium dihydrogen phosphate is 1:(0.7-1.1); Preferably, the disodium hydrogen phosphate is disodium hydrogen phosphate dodecahydrate; Preferably, the sodium dihydrogen phosphate is sodium dihydrogen phosphate dihydrate; Preferably, the content of the ionic strength maintaining agent in the exosome processing solution is 0.6-1.2% by weight; Preferably, the ionic strength maintaining agent is at least one of potassium chloride, sodium chloride, calcium chloride and magnesium chloride; further sodium chloride; Preferably, the content of the blocking agent in the exosome processing solution is 0.8-2.2% by weight; Preferably, the blocking agent comprises at least one of casein and collagen peptide and BSA; further comprises BSA; Preferably, the content of the surfactant in the exosome processing liquid is 0.05-0.6% by weight; Preferably, the surfactant comprises a nonionic surfactant; further comprises at least one of a nonionic surfactant containing a polyoxyethylene alcohol structure, a polyoxyethylene sorbitan fatty acid ester series, a polyoxyethylene octylphenyl ether series, and ND-glucose-N-methylalkaneamide; further comprises at least one of alcohol ethoxylate, polyoxyethylene-polyoxyalkylene block copolymer, Tween-20, Tween-40, Tween-80, Triton X-100, Triton X-114, Triton X-305, Triton X-405, Triton X-705, MEGA 8, and MEGA 10; further comprises Tween-20; Preferably, the content of the chelating agent in the exosome processing solution is 0.03-0.25% by weight; Preferably, the chelating agent comprises a water-soluble salt of ethylenediaminetetraacetic acid; further comprises disodium ethylenediaminetetraacetic acid; Preferably, the content of the sugar in the exosome processing solution is 0.8-2.2% by weight; Preferably, the sugar comprises trehalose; Preferably, the content of the preservative in the exosome processing liquid is 0.08-0.22% by weight; Preferably, the preservative comprises sodium azide or Proclin 300.
4. The exosome processing liquid according to claim 3, characterized in that: The content of the buffer substance in the exosome processing liquid is 2.2-3.8% by weight; Preferably, the content of tris(hydroxymethyl)aminomethane in the exosome processing solution is 1-2% by weight; Preferably, the content of the phosphate buffer in the exosome processing solution is 1.2-1.8% by weight; Preferably, the weight ratio of disodium hydrogen phosphate to sodium dihydrogen phosphate is 1:(0.8-1); Preferably, the content of the ionic strength maintaining agent in the exosome processing solution is 0.8-1% by weight; Preferably, the content of the blocking agent in the exosome processing solution is 1-2% by weight; Preferably, the content of the surfactant in the exosome processing liquid is 0.1 to 0.5% by weight; Preferably, the content of the chelating agent in the exosome processing solution is 0.05-0.2% by weight; Preferably, the content of the sugar in the exosome processing solution is 1-2% by weight; Preferably, the content of the preservative in the exosome processing liquid is 0.1 to 0.2% by weight; Preferably, the exosome treatment solution further comprises water, and the amount of water is the balance; Preferably, the pH of the exosome treatment solution is 6-8; further, 7-8.
5. A reagent or kit comprising the exosome processing solution according to any one of claims 1 to 4; Preferably, the reagent or kit is used for at least one of b1) to b4): b1) Detecting the presence or absence of exosome substances; b2) detecting the content of exosome substances; b3) diagnosing or assisting in the diagnosis of a disease, wherein the disease is diagnosed or assisted in the diagnosis by the presence or absence or content of exosome substances; b4) evaluating the severity of the disease, wherein the severity of the disease is evaluated by the content of exosome substances; Preferably, the substance comprises at least one of nucleic acid and protein; Preferably, the substance comprises protein; Preferably, the exosomes are derived from: one or more combinations of whole blood, serum, plasma, bronchoalveolar lavage fluid, and urine; Preferably, the reagent or kit is used for pre-treating exosomes and then used for at least one of b1) to b4).
6. A detection kit comprising at least one of c1) to c2), magnetic beads coated with capture antibodies, and detection antibodies labeled with luminescent substances: c1) the exosome processing liquid according to any one of claims 1 to 4; c2) the reagent according to claim 5; The detection kit is used for at least one of d1) to d4): d1) Detecting the presence or absence of exosomal proteins; d2) Detecting the content of exosomal proteins; d3) diagnosing or assisting in the diagnosis of a disease, wherein the disease is diagnosed or assists in the diagnosis by the presence or absence or content of exosome proteins; d4) evaluating the severity of the disease, wherein the severity of the disease is evaluated by the content of exosomal proteins; The capture antibody and / or the detection antibody specifically binds to the protein.
7. The detection kit according to claim 6, characterized in that: The luminescent substance comprises at least one of acridinium ester, horseradish peroxidase, and alkaline phosphatase; Preferably, the detection kit further comprises at least one of a luminescent substrate and a protein calibrator; Preferably, the protein is CA125, and the kit is used for at least one of e1) to e5): e1) Detection of the presence of exosomal CA125; e2) Detection of the content of exosomal CA125; e3) Diagnosis or auxiliary diagnosis of lung diseases; e4) Assess the severity of lung disease; e5) Diagnosis or auxiliary diagnosis of pulmonary fibrosis; Preferably, the lung disease comprises pneumonia or interstitial lung disease.
8. A detection system comprising at least one of f1) to f3) and a chemiluminescence instrument; f1) The exosome processing liquid according to any one of claims 1 to 4; f2) The reagent or kit according to claim 5; f3) The detection kit according to any one of claims 6 to 7.
9. A method for detecting the presence or content of exosome proteins, comprising the step of pretreating the exosomes using the exosome treatment solution according to any one of claims 1 to 4.
10. The method according to claim 9, characterized in that: The step of pre-treating the exosomes with the exosome treatment solution is specifically as follows: mixing the exosome treatment solution with the exosomes to react; Preferably, the volume ratio of the exosome treatment solution to the exosomes is 1:(2-30); Preferably, the reaction time is 5 to 120 min; Preferably, the reaction temperature is 25-42°C; Preferably, the exosomes are derived from: one or more combinations of whole blood, serum, plasma, bronchoalveolar lavage fluid, and urine; Preferably, the method further comprises the following steps: (1) mixing the pretreated exosomes with magnetic beads coated with capture antibodies, reacting to obtain magnetic beads-exosome complexes coated with capture antibodies; (2) mixing the capture antibody-coated magnetic bead-exosome complex with the luminescent-labeled detection antibody, and reacting them to obtain the capture antibody-coated magnetic bead-exosome-luminescent-labeled detection antibody complex; (3) mixing the magnetic beads coated with the capture antibody-exosome-luminescent substance-labeled detection antibody complex with the luminescent substrate, reacting, detecting the luminescence intensity, and obtaining the protein content in the exosome sample; Preferably, the reaction time in steps (1) and (2) is 5 to 120 minutes; Preferably, the reaction temperature in steps (1) and (2) is 25 to 42°C; Preferably, the method for obtaining the protein content in the exosome sample in step (3) is: using a protein calibrator to construct a standard curve by a standard curve method, and then calculating the protein content in the exosome sample according to the detected luminescence intensity.
11. Use of the exosome processing solution according to any one of claims 1 to 4 in at least one of a1) to a6); a1) Detecting the presence or absence of exosome substances; a2) Detecting the content of exosome substances; a3) preparing products for diagnosing or assisting in the diagnosis of diseases, wherein the diseases are diagnosed or assisted in the diagnosis by the presence or absence or content of exosome substances; a4) preparing a product for assessing the severity of a disease, wherein the severity of the disease is assessed by the content of exosome substances; a5) preparing a product for detecting the presence or absence of exosome substances; a6) preparing products for detecting the content of exosome substances; The substance comprises at least one of nucleic acid and protein.
12. The use according to claim 11, characterized in that: The nucleic acid comprises at least one of DNA and RNA; Preferably, the substance comprises protein; Preferably, the product comprises at least one of a reagent, a kit, and a detection system; Preferably, the exosomes are derived from: whole blood, serum, plasma, bronchoalveolar lavage fluid, urine or one or more combinations thereof.
13. Any of the following methods: a1) A method for detecting the presence or absence of exosome substances, comprising the step of pretreating the exosomes with the exosome treatment solution according to any one of claims 1 to 4; a2) A method for detecting the content of exosome substances, comprising the step of pretreating the exosomes with the exosome treatment solution according to any one of claims 1 to 4; The substance comprises at least one of nucleic acid and protein.
14. The method according to claim 13, characterized in that: The nucleic acid comprises at least one of DNA and RNA; Preferably, the substance comprises protein; Preferably, the exosomes are derived from: whole blood, serum, plasma, bronchoalveolar lavage fluid, urine or one or more combinations thereof.
15. Application of substances for detecting exosome CA125 in product preparation; The product is used for at least one of g1) to g3): g1) Diagnosis or auxiliary diagnosis of lung diseases; g2) Assess the severity of lung disease; g3) Diagnose or assist in the diagnosis of pulmonary fibrosis.
16. The use according to claim 15, characterized in that: The lung disease comprises pneumonia or interstitial lung disease; Preferably, the substance for detecting CA125 comprises a substance for detecting CA125 at the gene level and / or protein level; and further comprises a substance for detecting CA125 at the protein level; Preferably, the product is a reagent, a kit, a detection chip or a detection system; Preferably, the product comprises the exosome processing liquid according to any one of claims 1 to 4.
17. Any of the following methods: g1) A method for diagnosing or assisting in the diagnosis of a lung disease, comprising detecting the content of exosome CA125 in a test sample, Steps to achieve quantity and / or activity; g2) A method for assessing the severity of a lung disease, comprising the step of detecting the content, expression level and / or activity of exosome CA125 in a test sample; g3) A method for diagnosing or assisting in the diagnosis of pulmonary fibrosis, comprising the step of detecting the content, expression level and / or activity of exosome CA125 in a test sample.
18. The method according to claim 17, characterized in that: The lung diseases mentioned in g1) to g2) include pneumonia or interstitial lung disease; Preferably, in g1) to g3), the product described in claim 15 or 16 is used to detect the content, expression level and / or activity of exosomal CA125 in the test sample.
Citation Information
Patent Citations
Kit for detecting content of neutrophil gelatinase-associated lipocalin (NGAL)
CN104198732A
Complement C3 detection kit and use method thereof
CN107741501A
Gastrin-releasing peptide precursor diluent, and application and kit thereof
CN108333360A
Method for detecting content of KL-6 protein on exosome and application thereof
CN114113581A
CeRNA regulation and control network for early diagnosis or detection of non-small cell lung cancer and application of ceRNA regulation and control network
CN115125304A
